Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy – FierceBiotech
|
Sanofi drops Voyager's phase 2/3 Parkinson's gene therapy
FierceBiotech Sanofi has walked away from the Parkinson's gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |
